|
1JMQ
YAP65 (L30K mutant) WW domain in Complex with GTPPPPYTVG peptide
Deposited 2001-07-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
165–210(46 aa)
|
Mutation:L30K
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR sample composition
1.2 mM WW domain; 2.4 mM peptide GTPPPPYTVG; 10mM potassium phosphate buffer pH6; 100mM NaCl; 0.1 mM DTT; 0.1 mM EDTA, | 90% H20, 10% D20
NMR sample composition
1.2 mM WW domain; 2.4 mM peptide GTPPPPYTVG; 10mM potassium phosphate buffer pH6; 100mM NaCl; 0.1 mM DTT; 0.1 mM EDTA, | 100%D20
|
Resolution not provided
|
|
1K5R
YAP65 WW domain S24-Amino-Ethylsulfanyl-Acetic Acid mutant
Deposited 2001-10-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
165–204(40 aa)
Fragment:WW domain, residues 5-44
|
Mutation:S24/Amino-ethyl-sulfanyl-acetic acid
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100 mM NaCl;Pressure 1
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100 mM NaCl;Pressure 1
NMR sample composition
phosphate buffer 10 mM, Nacl 100mM, DTT 0.1mM, EDTA 0.1 mM, pH 6, WW domain 1.2 mM
Ligand 2.4 mM | H20 (10% D20)
NMR sample composition
phosphate buffer 10 mM, Nacl 100mM, DTT 0.1mM, EDTA 0.1 mM, pH 6 WW domain, 1.2 mM
Ligand 2.4 mM | D2O
|
Resolution not provided
|
|
1K9Q
YAP65 WW domain complexed to N-(n-octyl)-GPPPY-NH2
Deposited 2001-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
165–204(40 aa)
Fragment:Wild type WW domain
|
Not recorded
|
OCT N-OCTANE × 1
|
SOLUTION NMR
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR sample composition
phosphate buffer 10mM, NaCl 100mM, DTT 0.1mM, EDTA 0.1mM, pH 6, WW domain 1.2mM, ligand 2.4mM | H2O (10% D2O)
NMR sample composition
phosphate buffer 10mM, NaCl 100mM, DTT 0.1mM, EDTA 0.1mM, pH 6, WW domain 1.2mM, ligand 2.4mM | D2O
|
Resolution not provided
|
|
1K9R
YAP65 WW domain complexed to Acetyl-PLPPY
Deposited 2001-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
165–204(40 aa)
Fragment:Wild type WW domain
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR measurement conditions
pH 6;288 K;Ionic strength (raw mmCIF value) 100mM NaCl;Pressure 1
NMR sample composition
phosphate buffer 10mM, NaCl 100mM, DTT 0.1mM, EDTA 0.1mM, pH 6, WW domain 1.2mM, ligand 2.4mM | H2O (10% D2O)
NMR sample composition
phosphate buffer 10mM, NaCl 100mM, DTT 0.1mM, EDTA 0.1mM, pH 6, WW domain 1.2mM, ligand 2.4mM | D2O
|
Resolution not provided
|
|
2LAW
Structure of the second WW domain from human YAP in complex with a human Smad1 derived peptide
Deposited 2011-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
230–263(34 aa)
Fragment:second WW domain, residues 230-263
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;285 K;Ionic strength (raw mmCIF value) 0.420;Pressure ambient
NMR sample composition
1 mM NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LAX
Structure of first WW domain of human YAP in complex with a human Smad1 doubly-phosphorilated derived peptide.
Deposited 2011-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
170–205(36 aa)
Fragment:first WW domain, residues 170-205
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;285 K;Ionic strength (raw mmCIF value) 0.420;Pressure ambient
NMR sample composition
1 mM NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LAY
Structure of the first WW domain of human YAP in complex with a phosphorylated human Smad1 derived peptide
Deposited 2011-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
170–205(36 aa)
Fragment:residues 170-205
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;285 K;Ionic strength (raw mmCIF value) 0.420;Pressure ambient
NMR sample composition
1 mM NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LTV
YAP WW2 in complex with a Smad7 derived peptide
Deposited 2012-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
230–265(36 aa)
Fragment:WW2 domain (UNP residues 230-265)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.2;285 K;Pressure ambient
NMR sample composition
1 mM YAPWW2, 2 mM SMAD7, 20 mM [U-100% 2H] TRIS, 100 mM sodium chloride, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] YAPWW2, 3 mM SMAD7, 20 mM [U-100% 2H] TRIS, 100 mM sodium chloride, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LTW
YAP WW1 in complex with a Smad7 derived peptide
Deposited 2012-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
170–205(36 aa)
Fragment:WW1 domain (UNP residues 170-205)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7.2;285 K;Pressure ambient
NMR sample composition
1 mM YAPWW1, 2 mM SMAD7, 20 mM [U-100% 2H] TRIS, 100 mM sodium chloride, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-100% 13C; U-100% 15N] YAPWW1, 3 mM SMAD7, 20 mM [U-100% 2H] TRIS, 100 mM sodium chloride, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
3KYS
Crystal structure of human YAP and TEAD complex
Deposited 2009-12-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
50–171(122 aa)
Fragment:TEAD binding domain
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;277 K;0.1M sodium acetate, 2M sodium formate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.266
|
|
3KYS
Crystal structure of human YAP and TEAD complex
Deposited 2009-12-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
50–171(122 aa)
Fragment:TEAD binding domain
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;277 K;0.1M sodium acetate, 2M sodium formate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å
R-free 0.266
|
|
4RE1
Crystal structure of human TEAD1 and disulfide-engineered YAP
Deposited 2014-09-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
50–171(122 aa)
Fragment:TEAD BINDING DOMAIN (UNP RESIDUES 50-171)
|
Mutation:R87C, D93A, F96C, E100R
|
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;277 K;0.1M sodium acetate, 1.8M sodium formate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.248
|
|
4RE1
Crystal structure of human TEAD1 and disulfide-engineered YAP
Deposited 2014-09-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
50–171(122 aa)
Fragment:TEAD BINDING DOMAIN (UNP RESIDUES 50-171)
|
Mutation:R87C, D93A, F96C, E100R
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;277 K;0.1M sodium acetate, 1.8M sodium formate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.248
|
|
4REX
Crystal structure of the first WW domain of human YAP2 isoform
Deposited 2014-09-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
165–209(45 aa)
Fragment:WW domain (UNP residues 165-209)
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5;293 K;1.5 M ammonium sulphate, 0.1 M sodium acetate, 100 mM proline, 5 mM NDSB-201 and 5mM MBCD, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.60 Å
R-free 0.194
|
|
5OAQ
TEAD4 COMPLEXED WITH YAP PEPTIDE AND MYRISTATE (COVALENTLY BOUND)
Deposited 2017-06-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
GOL GLYCEROL × 1
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;15% PEG 3350,2% tacsimate, 0.1M NaCitrate
|
Resolution 1.95 Å
R-free 0.252
|
|
6G6X
14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide
Deposited 2018-04-03
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain P
124–133(10 aa)
|
Mutation:Proline 129 to beta3-proline
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
CL CHLORIDE ION × 8
NA SODIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.095 M HEPES, pH 7.1, 29% PEG 400, 0.19 M CaCl2, 5% glycerol
|
Resolution 1.13 Å
R-free 0.168
|
|
6G8P
14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide
Deposited 2018-04-09
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain P
124–133(10 aa)
Fragment:UNP residues 124-133
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
CA CALCIUM ION × 4
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.095 M HEPES, pH 7.1, 29% PEG 400, 0.19 M CaCl2, 5% glycerol
|
Resolution 1.90 Å
R-free 0.159
|
|
6G8Q
14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide
Deposited 2018-04-09
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain P
124–133(10 aa)
Fragment:UNP residues 124-133
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
CA CALCIUM ION × 2
CL CHLORIDE ION × 4
NA SODIUM ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.095 M HEPES, pH 7.1, 29% PEG 400, 0.19 M CaCl2, 5% glycerol
|
Resolution 1.85 Å
R-free 0.175
|
|
6GE3
X-ray structure of TEAD4 (wildtype) complexed with YAP (wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface
Deposited 2018-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;16% PEG 3350,2% tacsimate, 0.1M NaCit, pH 5.6
|
Resolution 1.85 Å
R-free 0.242
|
|
6GE4
TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 1.97A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M MgNitrate
|
Resolution 1.97 Å
R-free 0.241
|
|
6GE5
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;298 K;20% PEG 3350, 8% Tacsimate
|
Resolution 2.05 Å
R-free 0.238
|
|
6GE6
X-ray structure of TEAD4(E263A+Y429F mutant) complexed with YAP(wildtype): The role of residual flexibility and water molecules in the adaptation of a bound intrinsically disordered protein to mutations at a binding interface
Deposited 2018-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
PO4 PHOSPHATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;2M ammonium sulfate, 0.1M Bis-TRIS
|
Resolution 1.80 Å
R-free 0.238
|
|
6GEC
TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100);S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.70A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–99(40 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M NaTartrate
|
Resolution 1.70 Å
R-free 0.242
|
|
6GEE
TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–99(40 aa)
|
Mutation:S94A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;17% PEG 10000, 0.1M ammonium acetate, 0.1M Bis-TRIS
|
Resolution 1.96 Å
R-free 0.245
|
|
6GEG
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 2.23A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–99(40 aa)
|
Mutation:S94A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG 3350, 0.2M Na tartrate
|
Resolution 2.23 Å
R-free 0.236
|
|
6GEI
TEAD4 (216-434);E263A+Y429F COMPLEXED WITH YAP PEPTIDE (60- 100);S94A AND MYRISTOATE (COVALENTLY BOUND TO LYS344, NOT CYS367!) AT 1.65A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Mutation:S94A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 1
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;20% PEG 3350, 0.2M Na acetate
|
Resolution 1.65 Å
R-free 0.248
|
|
6GEK
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;25% PEG 3350, 0.2M MgCl2, 0.1M Bis-TRIS
|
Resolution 2.28 Å
R-free 0.246
|
|
6GEK
TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28A (P212121 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
Deposited 2018-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain M
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;25% PEG 3350, 0.2M MgCl2, 0.1M Bis-TRIS
|
Resolution 2.28 Å
R-free 0.246
|
|
6HIK
X-ray structure of TEAD4(Y429H) mutant) complexed with YAP (wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
Deposited 2018-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–99(40 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 1
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.6;298 K;1.4M Na/K PO4
|
Resolution 1.65 Å
R-free 0.237
|
|
6HIL
X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
Deposited 2018-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5;298 K;22% (w/v) PEG3350, 0.2M Na Malonate
|
Resolution 2.30 Å
R-free 0.267
|
|
6HIL
X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
Deposited 2018-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain O
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5;298 K;22% (w/v) PEG3350, 0.2M Na Malonate
|
Resolution 2.30 Å
R-free 0.267
|
|
6HIL
X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
Deposited 2018-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain M
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5;298 K;22% (w/v) PEG3350, 0.2M Na Malonate
|
Resolution 2.30 Å
R-free 0.267
|
|
6HIL
X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy
Deposited 2018-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain N
60–100(41 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5;298 K;22% (w/v) PEG3350, 0.2M Na Malonate
|
Resolution 2.30 Å
R-free 0.267
|
|
6Q2X
TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.1A (P41212 CRYSTAL FORM)
Deposited 2018-12-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain L
60–100(41 aa)
|
Not recorded
|
GOL GLYCEROL × 1
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.6;298 K;16% PEG 3350,2% tacsimate, 0.1M NaCit
|
Resolution 2.10 Å
R-free 0.253
|
|
8A8R
Crystal structure of TEAD4 in complex with YAP peptide
Deposited 2022-06-23
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain L
50–100(51 aa)
Chain M
50–100(51 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;50 mM sodium acetate trihydrate pH 4.6
50 mM magnesium acetate tetrahydrate
25% PEG400
|
Resolution 1.70 Å
R-free 0.243
|
|
8WRG
Solution structure of the TAD domain (450-504) of human transcriptional coactivator YAP1
Deposited 2023-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
450–504(55 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 120;Pressure 1
NMR sample composition
0.95 mM [U-99% 13C; U-99% 15N] YAP-TAD, 20 mM HEPES, 100 mM sodium chloride, 5 % v/v [U-99% 2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided
|
|
9FZA
TEAD1/YAP in complex with a reversible inhibitor N-[(4-phenoxyphenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide
Deposited 2024-07-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
51–110(60 aa)
|
Not recorded
|
CL CHLORIDE ION × 1
A1IHH ~{N}-[(4-phenoxyphenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4.6;293 K;2M Sodium Formate, 0.1M Sodium Acetate pH 4.6
|
Resolution 2.21 Å
R-free 0.262
|
|
9FZA
TEAD1/YAP in complex with a reversible inhibitor N-[(4-phenoxyphenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide
Deposited 2024-07-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
51–110(60 aa)
|
Not recorded
|
CL CHLORIDE ION × 1
A1IHH ~{N}-[(4-phenoxyphenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4.6;293 K;2M Sodium Formate, 0.1M Sodium Acetate pH 4.6
|
Resolution 2.21 Å
R-free 0.262
|